ABSTRACT
Access to urban natural space, including blue and greenspace, is associated with improved health. In 2021, the C40 Cities Climate Leadership Group set 2030 Urban Nature Declaration (UND) targets: "Quality Total Cover" (30% green area within each city) and "Equitable Spatial Distribution" (70% of the population living close to natural space). We evaluate progress toward these targets in the 96 C40 cities using globally available, high-resolution data sets for landcover and normalized difference vegetation index (NDVI). We use the European Space Agency (ESA)'s WorldCover data set to define greenspace with discrete landcover categories and ESA's Sentinel-2A to calculate NDVI, adding the "open water" landcover category to characterize total natural space. We compare 2020 levels of urban green and natural space to the two UND targets and predict the city-specific NDVI level consistent with the UND targets using linear regressions. The 96-city mean NDVI was 0.538 (range: 0.148, 0.739). Most (80%) cities meet the Quality Total Cover target, and nearly half (47%) meet the Equitable Spatial Distribution target. Landcover-measured greenspace and total natural space were strong (mean R 2 = 0.826) and moderate (mean R 2 = 0.597) predictors of NDVI and our NDVI-based natural space proximity measure, respectively. The 96-city mean predicted NDVI value of meeting the UND targets was 0.478 (range: 0.352-0.565) for Quality Total Cover and 0.660 (range: 0.498-0.767) for Equitable Spatial Distribution. Our translation of the area- and access-based metrics common in urban natural space targets into the NDVI metric used in epidemiology allows for quantifying the health benefits of achieving such targets.
ABSTRACT
BACKGROUND: CMV infection (CMV-I) remains an important complication of hematopoietic stem cell transplantation (HSCT). METHODS: This was a retrospective, single-center cohort study in HSCT recipients. Primary outcomes were adjusted cost and all-cause mortality. Secondary analyses investigated CMV risk factors and the effect of serostatus. RESULTS: Overall, 690 transplant episodes were included (allogeneic [n = 310]; autologous [n = 380]). All received preemptive CMV antiviral therapy at first detectable DNAemia. CMV-I occurred in 34.8% of allogeneic and 2.1% of autologous transplants; median time to onset was 45 days. In allogeneic HSCT recipients, the primary risk factor for CMV-I was CMV donor/recipient (D/R) serostatus. In a Markov multi-state model for allogeneic HSCT recipients, the hazard ratio for CMV-I and relapse was 1.5 (95% CI 0.8-2.8) and for CMV-I and mortality 2.4 (95% CI 0.9-6.5). In a multivariable model for all patients, CMV-I was associated with increased total cost (coefficient = 0.21, estimated incremental daily cost USD $500; P = 0.02). Cost was attenuated in allogeneic HSCT recipients (coefficient = 0.13, USD $699 vs $613, or $24 892 per transplant episode; P = 0.23). CMV disease (CMV-D) complicated 29.6% of CMV-I events in allogeneic HSCT recipients, but was not associated with an incrementally increased adjusted risk of mortality compared with CMV-I alone. CMV-I (56.4%) and CMV-D (19.8%) were significantly overrepresented in D-/R+ serostatus HSCT recipients, and mortality was higher in R+ HSCT recipients. CONCLUSIONS: Despite early preemptive antiviral treatment, CMV-I impacts clinical outcomes and cost after HSCT, but the impact on cost is less pronounced in allogeneic HSCT recipients compared with autologous HSCT recipients.
